Natco Pharma Launches Generic Pomalidomide Capsules for Blood Cancer in U.S.

Natco Pharma, in partnership with Breckenridge Pharmaceutical, has launched generic Pomalidomide capsules in the U.S. market. This drug, a generic version of Celgene's Pomalyst, treats adult patients with multiple myeloma and Kaposi sarcoma. Available in 1mg to 4mg strengths, it is distributed through specialty pharmacies and clinics. Natco expects 180 days of shared exclusivity and aims to improve access to affordable specialty medicines while expanding its oncology portfolio.